UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.84% | 4.40% | 20.87% | 3.35% | 9.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.84% | 4.40% | 20.87% | 3.35% | 9.24% |
| Cost of Revenue | 34.84% | 8.09% | 3.63% | -8.76% | -23.71% |
| Gross Profit | 5.11% | 4.00% | 23.08% | 4.94% | 14.24% |
| SG&A Expenses | 28.09% | 37.50% | 33.03% | 33.62% | 11.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.41% | 34.04% | 24.44% | 30.57% | 13.47% |
| Operating Income | -43.41% | -81.79% | -29.96% | -67.98% | -16.76% |
| Income Before Tax | -34.81% | -57.31% | -7.74% | -38.55% | -6.76% |
| Income Tax Expenses | 625.93% | -31.27% | 1,111.11% | -29.63% | 157.14% |
| Earnings from Continuing Operations | -35.80% | -44.19% | -8.20% | -38.39% | -6.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.80% | -44.19% | -8.20% | -38.39% | -6.86% |
| EBIT | -43.41% | -81.79% | -29.96% | -67.98% | -16.76% |
| EBITDA | -43.82% | -83.72% | -31.27% | -69.83% | -17.36% |
| EPS Basic | -6.12% | -10.84% | 18.91% | 11.82% | 32.87% |
| Normalized Basic EPS | -5.35% | -17.12% | 19.26% | 11.72% | 32.94% |
| EPS Diluted | -6.12% | -10.84% | 18.91% | 11.82% | 32.87% |
| Normalized Diluted EPS | -5.35% | -17.12% | 19.26% | 11.72% | 32.94% |
| Average Basic Shares Outstanding | 27.96% | 30.09% | 33.44% | 56.94% | 59.19% |
| Average Diluted Shares Outstanding | 27.96% | 30.09% | 33.44% | 56.94% | 59.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |